GlassScriptPhysician profile
Steven W Williams
NPI 1568451581
$6,814.47
in general payments reported to CMS, 2019-2025
18 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,155 · 2020: $688 · 2021: $1,264 · 2022: $494 · 2023: $492 · 2024: $492 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,167.52 | 2019-2024 | Da Vinci Surgical System |
| Stryker Corporation | $1,020.96 | 2019-2025 | Blueprint Patient Specific Instrumentation, Tornier Perform Reversed Glenoid |
| Davol INC. | $585.71 | 2019 | |
| Baxter Healthcare | $582.43 | 2023-2025 | Floseal, Tisseel, Perclot |
| Covidien LP | $413.21 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $369.28 | 2019 | |
| Medtronic, INC. | $170.82 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $127.02 | 2023 | Gore Bio-A Tissue Reinforcement |
| Tetraphase Pharmaceuticals, INC. | $112.27 | 2019 | |
| Tela Bio, INC. | $83.05 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $44.00 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $38.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $19.59 | 2023 | Keytruda |
| Conmed Corporation | $17.21 | 2022 | |
| Heron Therapeutics, INC. | $17.02 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $16.33 | 2024 | Axonics |
| Bard Peripheral Vascular, INC. | $15.46 | 2021 | |
| Solventum Corporation | $14.25 | 2025 | Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.